688 related articles for article (PubMed ID: 27637004)
21. Monoclonal Antibodies for the Management of Severe Asthma.
Rubinsztajn R; Chazan R
Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
[TBL] [Abstract][Full Text] [Related]
22. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
[TBL] [Abstract][Full Text] [Related]
23. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies.
Ingram JL; Kraft M
J Allergy Clin Immunol; 2012 Oct; 130(4):829-42; quiz 843-4. PubMed ID: 22951057
[TBL] [Abstract][Full Text] [Related]
24. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
25. Targeted Therapy for Severe Asthma: Identifying the Right Patients.
Low K; Bardin PG
Mol Diagn Ther; 2017 Jun; 21(3):235-247. PubMed ID: 28044257
[TBL] [Abstract][Full Text] [Related]
26. Severe asthma: what is new in the new millennium.
Ntontsi P; Samitas K; Zervas E; Gaga M
Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
[TBL] [Abstract][Full Text] [Related]
27. Emerging Biologics in Severe Asthma.
Pavord ID; Hilvering B; Shrimanker R
Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
[TBL] [Abstract][Full Text] [Related]
28. Phenotypes/endotypes-driven treatment in asthma.
Braido F; Tiotiu A; Kowal K; Mihaicuta S; Novakova P; Oguzulgen IK
Curr Opin Allergy Clin Immunol; 2018 Jun; 18(3):184-189. PubMed ID: 29601354
[TBL] [Abstract][Full Text] [Related]
29. What goes up must come down: biomarkers and novel biologicals in severe asthma.
Hilvering B; Pavord ID
Clin Exp Allergy; 2015 Jul; 45(7):1162-9. PubMed ID: 25640208
[TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.
Li H; Wang K; Huang H; Cheng W; Liu X
PLoS One; 2019; 14(1):e0211790. PubMed ID: 30703143
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-13 in asthma pathogenesis.
Wills-Karp M
Immunol Rev; 2004 Dec; 202():175-90. PubMed ID: 15546393
[TBL] [Abstract][Full Text] [Related]
32. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
33. Pitrakinra for asthma.
Antoniu SA; Cojocaru I
Expert Opin Biol Ther; 2010 Nov; 10(11):1609-15. PubMed ID: 20923253
[TBL] [Abstract][Full Text] [Related]
34. The use of biologic therapies for the management of pediatric asthma.
Lovinsky-Desir S
Pediatr Pulmonol; 2020 Mar; 55(3):803-808. PubMed ID: 31880870
[TBL] [Abstract][Full Text] [Related]
35. IL-13 antagonists in the treatment of atopic dermatitis.
Tubau C; Puig L
Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
[TBL] [Abstract][Full Text] [Related]
36. Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.
Nakamura Y; Sugano A; Ohta M; Takaoka Y
PLoS One; 2017; 12(11):e0188407. PubMed ID: 29155876
[TBL] [Abstract][Full Text] [Related]
37. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
Fajt ML; Wenzel SE
J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
[TBL] [Abstract][Full Text] [Related]
38. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
[TBL] [Abstract][Full Text] [Related]
39. Lebrikizumab treatment in adults with asthma.
Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
[TBL] [Abstract][Full Text] [Related]
40. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells.
Venkayya R; Lam M; Willkom M; Grünig G; Corry DB; Erle DJ
Am J Respir Cell Mol Biol; 2002 Feb; 26(2):202-8. PubMed ID: 11804871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
